Silexion Therapeutics Corp Ordinary SharesSLXN
About: Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
Employees: 14
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
3.19% less ownership
Funds ownership: 11.95% [Q3] → 8.76% (-3.19%) [Q4]
40% less funds holding
Funds holding: 5 [Q3] → 3 (-2) [Q4]
54% less capital invested
Capital invested by funds: $613K [Q3] → $281K (-$332K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Naz Rahman 0% 1-year accuracy 0 / 12 met price target | 607%upside $5 | Buy Maintained | 20 Mar 2025 |
Financial journalist opinion









